Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-15
Target enrollment:
Participant gender:
Summary
This is an open-label, non-control, non-randomized study to investigate the long-lasting
radiolabeled fibroblast activation protein inhibitor based radioligand therapy and evaluate
response to 177Lu-DOTA-EB-FAPI in patients with radioactive iodine refractory thyroid cancer.
A maximum of 3 cycles of various doses with 1.11GBq (30 mCi), 2.22GBq (60mCi), and 3.33GBq
(90 mCi) of 177Lu-DOTA-EB-FAPI will be injected intravenously separately. All patients will
undergo 68Ga-FAPI-46 and 18F-FDG PET/CT scans before and after the treatment.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University